Opex is more than top-line and executive compensation takes a chunk, when can we see green?

$Pacific Biosciences of California (PACB.US)$ usd 5.66. Opex is increasing while revenue followed laggingly. COGS is reasonable though... If revenue can't exceed opex, I don't see any reason to buy unless I hope for surprises or M&A deal.